Quia Pharma (QUIA) Q4 2024 earnings summary

Executive summary

• No revenue generated in 2024; operations focused on R&D and preparation for product launches.

• Significant net loss of -28,929 KSEK for the year, deepening from -16,523 KSEK in 2023.

• Ongoing financial strain, with only 2 KSEK in cash at year-end and reliance on new financing.

• Delays in Omega-3 product launch and ongoing negotiations for a major licensing deal with NZI.

• Facing potential delisting from Nasdaq First North due to alleged disclosure shortcomings.

Financial highlights

• Net sales remained at 0 KSEK for 2024, unchanged from 2023.

• Operating loss (EBIT) widened to -28,665 KSEK from -15,512 KSEK year-over-year.

• Net result after tax was -28,929 KSEK, compared to -16,523 KSEK in 2023.

• Cash flow for the year was -99 KSEK, with cash at year-end at 2 KSEK.

• A 15,000 KSEK impairment was recorded on an intangible asset related to Omega-3 tablets.

Outlook and guidance

• Omega-3 product launch now planned for H1 2025, delayed from original schedule.

• Ongoing rights issue could raise up to 8.4 MSEK if fully subscribed, supporting working capital and new product development.

• Company actively seeking partnerships and licensing deals to secure future revenue streams.